EUVIMEDEUVIMED entdecken
Open Access

Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States

John W Ostrominski iD, Janinne Ortega-Montiel iD, Helen Tesfaye iD, Caroline Alix, Elyse DiCesare, Sara J Cromer iD, Deborah J Wexler, Julie M Paik, Elisabetta Patorno

Annals of Internal Medicine · 2025-05 · 178 (5) · 620-633

DOI: 10.7326/annals-24-02870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025-05. Verfasst von John W Ostrominski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Division of Endocrinology, Diabetes and Hypertension, and Division of Pharmacoepidemiology and Pharmacoeconomics, Department…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Tirzepatide, Drug Utilization. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsTirzepatideDrug UtilizationHumansUnited StatesMiddle AgedMaleFemaleAdultAgedCohort StudiesDrug Approval

Substanzen

Hypoglycemic AgentsTirzepatide

Autor:innen und Institutionen

  • Cardiovascular Division, Division of Endocrinology, Diabetes and Hypertension, and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School,…
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (J.O.-M., H.T., C.A., E.D., E.P.).
  • Diabetes Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (S.J.C., D.J.W.).
  • Division of Pharmacoepidemiology and Pharmacoeconomics and Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (J.M.P.).

ORCID-Profile: John W Ostrominski, Janinne Ortega-Montiel, Helen Tesfaye, Sara J Cromer

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • FDA HHS

Zitieren

APA

Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., Alix, C., DiCesare, E., Cromer, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025). Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States. Annals of Internal Medicine, 178(5), 620-633. https://doi.org/10.7326/annals-24-02870

Vancouver

Ostrominski JW, Ortega-Montiel J, Tesfaye H, Alix C, DiCesare E, Cromer SJ, et al. Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States. Annals of Internal Medicine. 2025;178(5):620-633. doi:10.7326/annals-24-02870

BibTeX
@article{Ostrominski2025,
  author = {Ostrominski, John W and Ortega-Montiel, Janinne and Tesfaye, Helen and Alix, Caroline and DiCesare, Elyse and Cromer, Sara J and Wexler, Deborah J and Paik, Julie M and Patorno, Elisabetta},
  title = {Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {5},
  pages = {620--633},
  doi = {10.7326/annals-24-02870}
}
Kostenlos starten →